Home Categories Send inquiry

4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS 220000-87-3 Sorafenib Tosylate Intermediate Factory High Purity

Commercial Supply Sorafenib Tosylate and Related Intermediates:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6

Chemical Name 4-Chloro-N-Methyl-2-Pyridinecarboxamide
Synonyms 4-Chloro-N-Methylpicolinamide; N-Methyl-4-Chloropyridine-2-Carboxamide; 4-Chloro-N-Methylpyridine-2-Carboxamide
CAS Number 220000-87-3
CAT Number RF-PI165
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C7H7ClN2O
Molecular Weight 170.60 
Melting Point 41.0~438.0℃ 
Boiling Point 317.8℃ at 760 mmHg
Density 1.264 g/cm3
Solubility (Soluble in) Methanol, Ethylacetate
Shipping Conditions  Ambient
Brand Ruifu Chemical
Item Specifications
Appearance Off-White to Light Yellow Powder 
Identification (1) MS (2) 1H-NMR
Purity / Analysis Method 98.0%~101.0% (on the dried basis) (HPLC) 
Moisture (K.F) ≤1.0%
Loss on Drying ≤1.0%
Heavy Metals ≤20ppm
Single Impurity ≤1.0%
Total Impurities ≤2.0%
Test Standard Enterprise Standard
Usage Intermediate of Sorafenib Tosylate (CAS: 475207-59-1)

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-Chloro-N-Methyl-2-Pyridinecarboxamide (CAS: 220000-87-3) with high quality, it's an intermediate typically in the synthesis of Sorafenib Tosylate (CAS: 475207-59-1). Sorafenib Tosylate is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and HCC. Sorafenib Tosylate (CAS: 475207-59-1) can simultaneously affect tumor cells and tumor blood vessels.